| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
President & CSO | President & CSO | President & CEO +1 more
1 company
Jaume Pons last filed a Form 4 in February 2025, as President & CSO at ALXO. Jaume Pons's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Jaume Pons's trades have earned a strong insider score of 89/100 across 20 rated trades. Over a 12-month horizon, 90.0% of those trades were profitable, with an average 12-month return of +64.5%.
At the last filing, the largest reported position was 579,388 shares of ALXO. The ALXO filings lean toward selling, a net 318,736 shares.
Jaume Pons has 31 Form 4 filings on record from July 2020 to February 2025, all as President & CSO at Alx Oncology (ALXO), 2020–2025.
The 66 reported transactions were 47 open-market sales, 9 option exercises, 6 option or other derivative awards and 3 stock awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 21 sales worth about $10.8M.
The largest open-market sale was 16,700 shares of ALXO at an average $74.38 on September 20, 2021, about $1.2M. Twelve months later ALXO was down 85%.
5 of the 11 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
Shares as reported in the last Form 4 for each company; the most recent is from February 2025. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 19, 2025 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell | 1,326 | $1.15 | $1,525.17 | -0.2% | -64.0% | +118.5% | |
| Dec 30, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell | 10,796 | $1.58 | $17,059.84 | -1.8% | -62.5% | -28.3% | |
| Aug 14, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell | 1,937 | $2.58 | $4,997.46 | -0.3% | -48.1% | -74.6% | |
| Jul 11, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sale+OE10b5-1 | 20,000 | $7.90 | $158,076.00 | -3.3% | -79.0% | -93.7% | |
| Jul 1, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell | 10,758 | $5.82 | $62,598.65 | -1.8% | -69.6% | -92.8% | |
| Jun 4, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sale+OE10b5-1 | 20,000 | $8.43 | $168,652.00 | -3.2% | -74.4% | -93.6% | |
| May 6, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sale+OE10b5-1 | 20,000 | $15.92 | $318,334.00 | -3.2% | -82.7% | -96.8% | |
| Apr 16, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sale+OE10b5-1 | 50,000 | $14.20 | $710,195.00 | -7.6% | -44.8% | -96.1% | |
| Apr 4, 2024 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell10b5-1 | 20,000 | $11.15 | $223,036.00 | -3.1% | -50.2% | -95.4% | |
| Dec 29, 2023 | ALXO Alx Oncology Holdings Inc | President & CSO | Sell | 7,179 | $15.04 | $107,972.16 | -1.1% | -25.1% | -89.1% |